Occurrence of aminoglycoside-modifying enzymes genes (aac(6′)-I and ant(2′′)-I) in clinical isolates of Pseudomonas aeruginosa from Southwest Nigeria

African Health Sciences

Volumn 15, Issue 4, 2015, Pages 1277-1281

  Odumosu, Bamidele Tolulope ^a,b,c   Adeniyi, Bolanle A ^b   Chandra, Ram ^c  

^a UNIVERSITY OF LAGOS   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Aminoglycoside modifying enzymes; Antibiotics resistance; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; PIPERACILLIN; ACYLTRANSFERASE; AMINOGLYCOSIDE ACETYLTRANSFERASE; ANTIINFECTIVE AGENT; BACTERIAL DNA;

AME GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NIGERIA; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; GENETICS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

ACETYLTRANSFERASES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; NIGERIA; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA;

EID: 84954499600     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: 10.4314/ahs.v15i4.29     Document Type: Article

References (21)

1. Lister PD, Wolte, DJ, Hanson ND (2009). Antibacterial- resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22, 582-610.
2. Aloush V, Navon-Venezia S, Seigman I, Cabili S, Carmeli, Y (2006). Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical. Impact Antimicrob Agent Chemother. 50, 43-48.
3. Rello J, Allegri C, Rodriguez A Vidaur L, Sirgo G, Gomez F et al. (2006). Risk factors for ventilator associated pneumonia by Pseudomonas aeruginosa in pres-ence of recent antibiotic exposure. Anesthesiology. 105: 709-14.
4. Otaibi FE, Al-Hulaily FF (2012). Imipenem-resistant Psedomonas aeruginosa: Epidemiology and susceptibility patterns at a Teaching Hospital in Riyadh, Saudi Arabia. Afr. J. Microbiol. Res. 6, 1527 - 1533
5. Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999). Nosocomial infections in medical intensive care units in the United States. Crit. Care Med. 27, 887-892.
6. Dimatatac EL, Alejandria MM, Montalban C, Pineda C, Ang C, Delino RL (2003). Clinical outcomes and costs of care of antibiotic resistant Pseudomonas aeruginosa infections. Phil. J. Microbiol. Infect. Dis. 32, 159-167.
7. Dubois V, Poirel L, Marie C, Arpin C, Nordmann P, Quentin C (2002). Molecular characterization of a novel class 1 integron containing blaGES-1 and fused product of aac(3)-Ib/aac 69-Ib9 gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 46, 638-645.
8. Poole K (2005a). Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49, 479-487.
9. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes, D et al (1997). The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis. 24, 46-62.
10. Poole K (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56, 20-51.
11. Doi Y and Arakawa Y (2007). 16S ribosomal RNA methylation: emerging resistance mechanisms against aminoglycosides. Clin Infect Dis 45, 88-94.
12. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (2003). Manual of Clinical Microbiology. 8th edition. Washington DC: ASM Press.
13. CLSI: Performance standards for antimicrobial susceptibility testing; 20th informational supplement. M100-S20. Wayne, Pa: Clinical and Laboratory Standards Institute; 2010.
14. Odumosu BT, Adeniy, BA, Chandra R (2013). Analysis of integrons and associated gene cassettes in clinical isolates of multidrug resistant Pseudomonas aeruginosa from Southwest Nigeria. Annals Clin Microbiol Antimicrob. 12, 29-36
15. Kim JY, Park YJ, Kwon HJ, Han K, Kang MW, Woo GJ (2008). Occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa: a Korean nationwide study. J Antimicrob Chemother. 62, 479-483.
16. Falagas ME, Grammatikos AP, Michalopoulos A (2008). Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 6, 593-600.
17. Žáková A, Talábová E, Giamarellou H, Mačičková T, Michálková-Papajová D, Bagová M et al. (2001). Comparison of aminoglycoside resistance mechanisms in Pseudomonas aeruginosa isolates from Slovakia and Greece. Biologia, Bratislava. 56, 617-23.
18. Chaudhary M, and Payasi A (2014). Resistance Patterns and Prevalence of the Aminoglycoside Modifying Enzymes in Clinical Isolates of Gram Negative Pathogens. Global J. Pharmacol. 8, 73-79.
19. Vaziri F, Peerayeh SN, Nejad QB, Farhadian A (2011). The prevalence of aminoglycoside-modifying enzyme genes (aac (6’)-I, aac (6’)-II, ant (2”)-I, aph (3’)- VI) in Pseudomonas aeruginosa. Clinics. 66, 1519-1522.
20. Vakulenko SB Mobashery S (2003). Versatility of Aminoglycosides and Prospects for Their Future. Clin. Microbiol. Rev. 16, 430-50.
21. Shaw KJ, Rather PN, Hare RS, Miller GH (1993). Molecular Genetics of Aminoglycoside Resistance Genes and Familial Relationships of the Aminoglycoside- Modifying Enzymes. Microbiological Reviews. 57, 138-163.